Drug Profile
Ormeloxifene - Central Drug Research Institute
Alternative Names: Centchroman; Centron; Chhaya; Choice-7; Novex; Novex-DS; Saheli; Sevista; Tatkal-72Latest Information Update: 26 Apr 2022
Price :
$50
*
At a glance
- Originator Central Drug Research Institute
- Developer Hindustan Latex
- Class Chromans; Contraceptives; Pyrrolidines; Small molecules
- Mechanism of Action Estrogen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Metrorrhagia; Pregnancy
- Phase II Breast cancer
Most Recent Events
- 26 Apr 2022 Phase II trial is still ongoing for Breast cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in India (PO) (CTRI2018-06-014620)
- 31 Dec 2006 Early research in Metrorrhagia in India (PO)
- 16 Jul 2001 A study in volunteers has been added to the adverse events and pharmacokinetics sections